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Abstract
Background: The study aimed to assess 52-week efficacy and safety of secukinumab self-administration by
autoinjector in patients with active psoriatic arthritis (PsA) in the FUTURE 3 study (ClinicalTrials.gov NCT01989468).
Methods: Patients (≥ 18 years of age; N = 414) with active PsA were randomized 1:1:1 to subcutaneous (s.c.)
secukinumab 300 mg, 150 mg, or placebo at baseline, weeks 1, 2, 3, and 4, and every 4 weeks thereafter. Per clinical
response, placebo-treated patients were re-randomized to s.c. secukinumab 300 or 150 mg at week 16 (nonresponders) or
week 24 (responders) and stratified at randomization by prior anti-tumor necrosis factor (TNF) therapy (anti-TNF-naïve, 68.
1%; intolerant/inadequate response (anti-TNF-IR), 31.9%). The primary endpoint was the proportion of patients achieving at
least 20% improvement in American College of Rheumatology response criteria (ACR20) at week 24. Autoinjector usability
was evaluated by Self-Injection Assessment Questionnaire (SIAQ).
Results: Overall, 92.1% (300 mg), 91.3% (150 mg), and 93.4% (placebo) of patients completed 24 weeks, and 84.9%
(300 mg) and 79.7% (150 mg) completed 52 weeks. In the overall population (combined anti-TNF-naïve and
anti-TNF-IR), ACR20 response rate at week 24 was significantly higher in secukinumab groups (300 mg, 48.2%
(p < 0.0001); 150 mg, 42% (p < 0.0001); placebo, 16.1%) and was sustained through 52 weeks. SIAQ results
showed that more than 93% of patients were satisfied/very satisfied with autoinjector usage. Secukinumab was
well tolerated with no new or unexpected safety signals reported.
Conclusions: Secukinumab provided sustained improvements in signs and symptoms in active PsA patients
through 52 weeks. High acceptability of autoinjector was observed. The safety profile was consistent with that
reported previously.
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Background
Psoriatic arthritis (PsA) is an immune-mediated chronic
inflammatory disease that affects peripheral and axial
joints, entheses, and skin and is associated with impaired
physical function and poor quality of life [1–3].
Nonsteroidal anti-inflammatory drugs (NSAIDs) and
nonbiologic disease-modifying anti-rheumatic drugs
(DMARDs) are used as first-line therapy for PsA;
however, these often only partially control disease
symptoms [4].
Introduction of tumor necrosis factor (TNF)-blocking
therapy improved the treatment of patients with PsA
[5–7]. However, relapse or loss of response to anti-TNF
therapy and adverse events (AEs) are common,
highlighting an unmet clinical need for improved disease
control [8, 9].
The interleukin-17A (IL-17A) pathway is proposed to
play a key role in the pathogenesis of PsA [10].
Secukinumab, a fully human monoclonal antibody that
selectively neutralizes IL-17A, has shown significant effi-
cacy in the treatment of moderate to severe psoriasis
and PsA, with a rapid onset of action, sustained
responses, and a favorable safety profile [6, 11–14].
Placebo-controlled, double-blind, phase III trials with
secukinumab (FUTURE 1 and FUTURE 2) have
reported significant improvements in key clinical do-
mains of PsA sustained through week 104 in FUTURE 2
and week 156 in FUTURE 1 [6, 15–19].
Here we report the primary efficacy and safety re-
sults over a 52-week period from the FUTURE 3
study (ClinicalTrials.gov NCT01989468), which in-
volves subcutaneous (s.c.) self-administration of secu-
kinumab via autoinjector in patients with active PsA.
Methods
Patients
Patients included were ≥ 18 years of age, meeting the
ClASsification criteria for Psoriatic ARthritis (CASPAR)
and having active disease, defined as at least three tender
joints out of 78 and at least three swollen joints out of
76, despite previous treatment with NSAIDs, DMARDS,
or anti-TNF agents. Patients treated with up to three
anti-TNF agents could enroll if they had an inadequate
response for at least 3 months or had stopped anti-TNF
therapy due to safety/tolerability reasons (anti-TNF-IR),
and had an appropriate washout period before
randomization.
Concomitant use of oral corticosteroids (≤ 10 mg/day
prednisone or equivalent) and methotrexate (MTX; ≤ 25
mg/week) was allowed if the dose was stable for at least
2 weeks and 4 weeks before randomization, respectively.
The exclusion criteria were: previous use of any bio-
logical agent other than anti-TNF agents or the use of >
3 anti-TNF agents; active inflammatory diseases other
than PsA; active infection in the 2 weeks before
randomization, or a history of ongoing, chronic, or re-
current infections, or evidence of tuberculosis infection;
history of malignant disease within the past 5 years (ex-
cluding basal cell carcinoma or actinic keratosis, in-situ
cervical cancer, or noninvasive malignant colon polyps);
and pregnancy.
Study design
FUTURE 3 is an ongoing, multicenter, randomized,
double-blind, double-dummy, placebo-controlled, parallel-
group, 3-year study assessing the use of s.c. secukinumab
self-administration with an autoinjector in patients with
active PsA.
The study is being conducted at 74 centers across
Australia, Bulgaria, Canada, Czech Republic, Germany,
Italy, the Netherlands, Russia, Spain, Switzerland, the
United Kingdom, and the USA. Following a 10-week
screening period, eligible patients were randomized
(1:1:1) by means of an interactive response technology
(IRT) to one of two secukinumab dose groups (secuki-
numab 300 mg or 150 mg) or placebo.
Patients in the secukinumab groups received s.c. secu-
kinumab at a dose of 300 mg (2 × 1.0 ml autoinjector)
or 150 mg (1.0 ml autoinjector + 1.0 ml placebo autoin-
jector) at baseline, weeks 1, 2, 3, and 4, and every 4
weeks thereafter. Patients in the placebo group (2 × 1.0
ml placebo autoinjector) were treated according to the
same administration schedule as the active drug.
Patients were stratified at randomization based on pre-
vious anti-TNF therapy use as anti-TNF-naïve or anti-
TNF-IR; at least 60% of patients in each treatment arm
(secukinumab 300 mg, secukinumab 150 mg, and
placebo) were anti-TNF-naïve.
At week 16, patients were classified either as
responders (≥ 20% improvement from baseline in both
tender joint count (TJC) and swollen joint count (SJC))
or nonresponders. Placebo patients were re-randomized
to receive secukinumab 300 or 150 mg s.c. every 4 weeks
at week 16 (nonresponders) or week 24 (responders;
Additional file 1: Figure S1).
The study was conducted in accordance with the
principles of the Declaration of Helsinki. All centers
received approval from independent ethics committees
(IECs) or institutional review boards (IRBs). The
names of IECs or IRBs that approved the study and
the associated approval numbers where applicable are
presented in Additional file 1: Table S1. Patients pro-
vided written informed consent before starting the
study-related procedures.
Outcomes
The primary efficacy endpoint was the proportion of pa-
tients achieving an American College of Rheumatology
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response criterion 20 (ACR20) response at week 24.
Secondary endpoints assessed as part of a predefined
hierarchical hypothesis-testing strategy at week 24 in-
cluded: proportion of patients with an ACR50 response;
change from baseline in 28-joint Disease Activity Score
based on C-reactive protein (DAS28-CRP); proportion
of patients achieving Psoriasis Area Severity Index
(PASI) 75 response in patients with psoriasis affecting ≥
3% of body surface area; change from baseline in score
of the Short Form-36 Physical Component Summary
(SF-36 PCS); PASI 90 response; change from baseline in
Health Assessment Questionnaire—Disability Index
(HAQ-DI) score; and resolution of dactylitis and
enthesitis.
Exploratory endpoints were: Functional Assessment of
Chronic Illness Therapy—Fatigue (FACIT-Fatigue); change
from baseline in patient’s assessment of PsA pain (visual
analog scale (VAS)); assessments of all primary and sec-
ondary endpoints up to week 52; and subgroup analyses
according to previous anti-TNF use (ACR20/50 and
DAS28-CRP assessments) and concomitant MTX use
(ACR20/50 assessments).
Autoinjector usability was assessed based on investiga-
tor/site staff rating scores of successful, hazard-free self-
injection and patient rating of autoinjector acceptability.
The Self-Injection Assessment Questionnaire (SIAQ)
was used to evaluate patients’ perceptions before and
after self-injection [20]. The SIAQ PRE module was
completed by patients before the first self-injection
during the baseline visit and assessed three domains
(feelings about injections (FL), self-confidence (CO), and
satisfaction with self-injection (SA)). The POST module
included four domains (FL, CO, pain and skin reactions,
and SA) at baseline and weeks 1 and 2.
Safety assessments included evaluation of all AEs and
serious AEs (SAEs), together with electrocardiograms,
physical examination, vital signs and laboratory assess-
ments, and assessment of anti-secukinumab antibody
development (immunogenicity).
Statistical analysis
A sample size of 135 patients per group was estimated to
provide about 98% power to detect a treatment difference
for the primary endpoint of ACR20 response at week 24
assuming a placebo response of 21% and a secukinumab
response of 47% based on Fisher’s exact test. Evaluations
of efficacy were performed on the full analysis set (FAS),
which comprised all randomized patients to whom treat-
ment had been assigned. Closed testing procedures were
used to maintain a family-wise error rate of 5% across the
secukinumab groups and endpoints (details presented
in Additional file 1).
Primary and other binary endpoints were evaluated by
means of logistic regression, with treatment and anti-
TNF response status as factors and weight as a covariate.
Baseline PASI score was a covariate in PASI 75 and PASI
90 analyses. Missing values, including those due to
discontinuation of study treatment, were imputed as fail-
ures to achieve the given response (nonresponses). Also,
patients who did not achieve response based on joint
count at week 16 were imputed as nonresponders at
week 20 and week 24 (rescue penalty).
Between-group differences in continuous variables were
evaluated with the use of a mixed-model repeated-
measures (MMRM) approach, with missing data assumed
to be missing at random, with treatment, assessment visit,
and anti-TNF response status as factors. Weight and base-
line values of endpoints were included in the model as
continuous covariates, and treatment by analysis visit and
baseline score by analysis visit as interaction terms. PASI
75/90 scores were also analyzed using a modified rescue
penalty (Additional file 1). Subgroup analyses were carried
out on the basis of previous anti-TNF therapy or con-
comitant MTX treatment.
SIAQ domain scores ranging from 0 to 10 were calcu-
lated to assess self-injection experience, with higher
scores indicating a better experience for a patient. The
percentage of patients who successfully completed self-
injection per the instructions for use (IFU) was reported
for the overall population at week 1 and SIAQ domain
scores were provided by visit.
Safety endpoints were evaluated in the safety set,
which included all patients who received at least one
dose of the study drug; these endpoints were summa-
rized descriptively. Safety results are presented for the
placebo-controlled period and the entire safety-reporting
period, which included all safety data up to the cutoff
date of the last patient’s week 52 visit.
Results
Patients
Overall, 414 patients with active PsA were enrolled in
FUTURE 3. At baseline, demographic and disease char-
acteristics were generally balanced across the treatment
groups (Table 1). The mean time since the first diagnosis
of PsA ranged from 6.6 to 8.3 years. Approximately two-
thirds of the patients were anti-TNF-naïve (68.1%) and
one-third (31.9%) were anti-TNF-IR, with patients in
both subgroups evenly distributed across treatment
groups; 53.8% of anti-TNF-IR patients were exposed to
≥ 2 anti-TNF agents. About half (47.6%) of the patients
were using MTX at baseline (50.4%, secukinumab 300
mg; 42.8%, secukinumab 150 mg; 49.6%, placebo; Table
1). Of the 414 patients, 128/139 patients (92.1%, secuki-
numab 300 mg), 126/138 patients (91.3%, secukinumab
150 mg), and 128/137 patients (93.4%, placebo) com-
pleted 24 weeks and 337/414 patients (81.4%) completed
52 weeks (Fig. 1). The most common reasons for
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discontinuation by 52 weeks were lack of efficacy (5.0%,
secukinumab 300 mg; 7.2%, secukinumab 150 mg) and
AEs (5.8%, secukinumab 300 mg; 4.3%, secukinumab
150 mg). The most common reason for discontinuation
in the initial placebo nonresponder group was lack of
efficacy (4.5%, patients re-randomized to secukinumab
300 mg; 11.6%, patients re-randomized to secukinu-
mab 150 mg).
Efficacy
The primary endpoint was met, demonstrating efficacy
of secukinumab (150 mg and 300 mg) versus placebo in
the ACR20 response at week 24. ACR20 response rates
using the conservative estimate of efficacy with missing
values imputed as nonresponse were significantly higher
in the secukinumab 300 mg (48.2%; p < 0.0001) and 150
mg (42.0%; p < 0.0001) groups versus placebo (16.1%;
Fig. 2). Similarly, ACR50 response rates at week 24 were
also significantly higher in the secukinumab 300 mg
(34.5%; p < 0.0001) and 150 mg (18.8%; p < 0.05) groups
versus placebo (8.8%; Fig. 3).
ACR20/50 response rates were higher with secukinu-
mab than with placebo in both the anti-TNF-naïve and
anti-TNF-IR patients, with response generally being
Table 1 Demographic and baseline characteristics of patients






Age (years), mean (SD) 49.3 (12.9) 50.1 (11.7) 50.1 (12.6)
Male, n (%) 67 (48.2) 61 (44.2) 59 (43.1)
Race, n (%)
White 130 (93.5) 129 (93.5) 133 (97.1)
American Indian or Alaska Native 0 2 (1.4) 0
Asian 3 (2.2) 2 (1.4) 4 (2.9)
Other 6 (4.3) 5 (3.6) 0
Weight (kg), mean (SD) 87.1 (19.4) 87.1 (20.0) 82.6 (18.5)
Number of previous anti-TNF treatments for PsA, n (%)
0 95 (68.3) 94 (68.1) 93 (67.9)
1 19 (13.7) 22 (15.9) 20 (14.6)
≥ 2 25 (18.0) 22 (15.9) 24 (17.5)
Time since diagnosis of PsA (years), mean (SD) 8.3 (9.2) 7.7 (8.5) 6.6 (6.9)
MTX use at randomization, n (%) 70 (50.4) 59 (42.8) 68 (49.6)
Systemic glucocorticoid use at randomization, n (%) 23 (16.5) 24 (17.4) 32 (23.4)
Anti-TNF-naïve, n (%) 95 (68.3) 94 (68.1) 93 (67.9)
Patients with specific disease characteristics, n (%)
Psoriasis ≥ 3% of BSA 62 (44.6) 68 (49.3) 59 (43.1)
Presence of dactylitis 46 (33.1) 36 (26.1) 36 (26.3)
Presence of enthesitis 88 (63.3) 95 (68.8) 98 (71.5)
Disease and quality-of-life scores, mean (SD)
TJC (78 joints) 19.7 (14.8) 23.3 (18.1) 21.9 (16.2)
SJC (76 joints) 8.9 (6.4) 11.2 (9.2) 10.3 (8.6)
DAS28-CRP 4.5 (1.0) 4.6 (1.1) 4.7 (1.1)
PASIa 10.1 (8.6) 8.8 (6.4) 10.4 (9.0)
Physician’s global assessment (VAS) 51.8 (19.7) 55.2 (16.7) 54.8 (18.1)
HAQ-DI 1.1 (0.7) 1.2 (0.6) 1.2 (0.6)
PsA pain (VAS) 54.8 (23.8) 54.4 (21.4) 53.3 (23.8)
Patient’s global assessment (VAS) 59.9 (20.8) 59.8 (22.1) 60.6 (20.9)
SF-36 PCS 39.2 (8.4) 37.9 (7.6) 37.4 (8.5)
BSA body surface area, DAS28-CRP 28-joint Disease Activity Score using C-reactive protein, HAQ-DI Health Assessment Questionnaire—Disability Index, MTX metho-
trexate, N number of randomized patients, PASI Psoriasis Area and Severity Index, PsA psoriatic arthritis, SD standard deviation, SF-36 PCS Short Form-36 Physical
Component Summary, SJC swollen joint count, TJC tender joint count, TNF tumor necrosis factor, VAS visual analog scale
aAssessed in patients with psoriasis on at least 3% of their BSA
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higher in the anti-TNF-naïve population (Figs. 2
(ACR20) and 3 (ACR50)). At week 24, in anti-TNF-naïve
patients the ACR20/50 response rates were 51.6%/41.1%
(secukinumab 300 mg), 45.7%/24.5% (secukinumab 150
mg), and 19.4%/11.8% (placebo). In the anti-TNF-IR pa-
tients, the ACR20/50 response rates were 40.9%/20.5%
in secukinumab 300 mg and 34.1%/6.8% in secukinumab
150 mg versus 9.1%/2.3% in the placebo group (Figs. 2
and 3).
ACR20/50 responses were sustained at week 52 in the
overall population (58.3%/33.1% in secukinumab 300 mg
group and 47.1%/27.5% in secukinumab 150 mg group).
Response rates were also maintained in patients strati-
fied by anti-TNF status through 52 weeks of treatment
(Figs. 2 and 3).
Secondary endpoints were assessed in a hierarchical
order. At week 24, statistical significance versus placebo
was achieved for all secondary endpoints in the secuki-
numab 300 mg group. In the secukinumab 150 mg
group, statistical significance was achieved for DAS28-
CRP and PASI 75 scores. Clinical responses at week 24
across secondary endpoints with secukinumab 300 mg
and 150 mg were sustained through 52 weeks of treat-
ment (Table 2).
Analysis of PASI 75/90 scores at week 24 using the
modified rescue penalty (Additional file 1) resulted in
61.3%/41.9% and 55.9%/39.7% responses with secukinu-
mab 300 and 150 mg, respectively, versus 11.9%/8.5%
for placebo (p < 0.001).
In anti-TNF-naïve patients, mean change from base-
line in the DAS28-CRP score at week 24 was −1.64 ±
0.10 (p < 0.0001) and −1.33 ± 0.10 (p < 0.01) in the secu-
kinumab 300 and 150 mg groups, respectively, as
compared with −0.78 ± 0.14 in the placebo group. In
anti-TNF-IR patients, mean change from baseline in
DAS28-CRP score was −1.43 ± 0.20 (p < 0.01) and −1.06
± 0.19 (p > 0.05) in the secukinumab 300 and 150 mg
groups, respectively, as compared with −0.49 ± 0.26 in
the placebo group. The mean change from baseline in
DAS28-CRP score observed with secukinumab at week
24 was sustained through week 52 regardless of anti-
TNF status (anti-TNF-naïve, −1.68 ± 0.10 (secukinumab
300 mg) and −1.44 ± 0.11 (secukinumab 150 mg); anti-
TNF-IR, −1.56 ± 0.21 (secukinumab 300 mg) and −1.47
± 0.21 (secukinumab 150 mg)).
At week 24, ACR20/50 response rates were higher
with secukinumab than with placebo in patients with
and without concomitant MTX use, and the
responses were maintained through 52 weeks of treat-
ment (Additional file 1).
At week 24, mean change from baseline in patient’s
assessment of PsA pain (VAS) was higher in both the
secukinumab 300 and 150 mg groups versus placebo
and mean change from baseline in FACIT-Fatigue was
higher only in the secukinumab 300 mg group. The
changes observed at week 24 in both exploratory end-
points were sustained through 52 weeks of treatment
(Table 2).
Observed data at weeks 24 and 52 for the primary,
secondary, and exploratory endpoints are presented in
Additional file 1: Table S2.
Autoinjector usability and satisfaction assessment
More than 99% of patients in the overall population suc-
cessfully self-administrated the study drug at week 1.
The most common hazard was needle stick in a
Fig. 1 Patient disposition up to week 52
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noncritical area, observed in nine patients overall at
randomization and week 1. The scores of FL, CO, and
SA were high pre self-injection (FL = 8.22, CO = 6.52,
and SA = 6.80) and remained high at week 2 (FL = 8.81,
CO = 7.84, and SA = 8.39) in all patients. Patient-
reported scores of the three domains by visit and treat-
ment are shown in Additional file 1: Table S3. More
than 90% of total patients reported no pain and reaction
during or after the injection, and ≥ 88% of patients were
either satisfied or very satisfied with the use of the auto-
injector devise and found the usage of an autoinjector
easy or very easy, with no external help required, as
assessed by SIAQ at week 2.
Safety
The incidence of AEs during the placebo-controlled
period was similar across the study groups, with a
slightly higher number of SAEs reported in the placebo
Fig. 2 ACR20 response rates through week 52 in the overall population (a) and by anti-TNF status (b, c). *p < 0.0001, §p < 0.01, ‡p < 0.05 versus
placebo. p values adjusted for multiplicity of testing for overall population at week 24. Missing values imputed as nonresponse (nonresponder
imputation) through week 52. ACR20 20% improvement in American College of Rheumatology response criteria, IR inadequate response, s.c.
subcutaneous, TNF tumor necrosis factor
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group (Table 3). Treatment-emergent AEs were reported
in 54.7%, 58.0%, and 56.2% of patients receiving secuki-
numab 300 mg, secukinumab 150 mg, and placebo,
respectively. There were no deaths reported during the
placebo-controlled 16-week period. Over the entire
treatment period (mean ± SD exposure, secukinumab
398.1 ± 112.1 days and placebo 130.7 ± 29.8 days),
exposure-adjusted incidence rates (EAIRs) of AEs among
patients receiving secukinumab 300 and 150 mg were
194.9 and 192.5 per 100 patient-years, respectively; the
corresponding values for SAEs were 8.8 and 10.2 per
100 patient-years, respectively (Table 3). The most fre-
quent SAEs included infections and infestations and
musculoskeletal and connective tissue disorders with an
EAIR of 1.8 and 2.1, respectively. Details of SAEs
through the entire safety period are presented in
Additional file 1: Table S4. Two deaths were reported
in the secukinumab 150 mg group during the entire
52-week analysis period: one pancreatic carcinoma
and one small cell lung cancer (additional details
Fig. 3 ACR50 response rates through week 52 in the overall population (a) and by anti-TNF status (b, c). *p < 0.0001, ‡p < 0.05 versus placebo. p values ad-
justed for multiplicity of testing for overall population at week 24. Missing values imputed as nonresponse (nonresponder imputation) through week 52.
ACR50 50% improvement in American College of Rheumatology response criteria, IR inadequate response, s.c. subcutaneous, TNF tumor necrosis factor
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regarding these patients are available in Additional file 1).
Myocardial infarction was reported in one patient with a
history of smoking and hyperlipidemia and who was a
long-time NSAID user. Suicidal ideation was reported in
two patients (one patient each in secukinumab 150 and
300 mg groups); both patients had a prior history of psy-
chiatric disorders and were on related medications. Can-
dida infections were reported for 14 patients in the
secukinumab dose groups that included eight oral candid-
iasis (three patients in 300 mg group and five patients in
150 mg group) and four vulvovaginal candidiasis (two pa-
tients each in secukinumab 300 mg and secukinumab 150
mg groups). These candida infections were diagnosed as
nonserious, mild, or moderate in severity by the investiga-
tors and did not lead to study withdrawal.
Malignant or unspecified tumors (excluding basal cell
and squamous cell carcinomas) were reported in three pa-
tients each in the secukinumab 300 mg and 150 mg
groups. One patient in the 300 mg group reported inflam-
matory bowel disease (moderate). Neutropenia was re-
ported in three patients: one patient in the 300 mg group
and two patients in the 150 mg group. This included
Grade 3 leukopenia (one patient each in the 300 and 150
mg groups) and Grade 3 neutropenia (one patient in 150
mg group). Injection-site reactions were reported by six
patients in the secukinumab 300 mg and seven patients in
the secukinumab 150 mg group. Treatment-emergent
anti-secukinumab antibodies (positive during study but
negative at baseline) were detected in four patients, while
neutralizing antibodies were not detected in any patients.
Table 2 Efficacy of secukinumab at weeks 24 and 52 in the overall populationa






ACR20 response, n/N (%) 24 67/139 (48.2)* 58/138 (42.0)* 22/137 (16.1)
52 81/139 (58.3) 65/138 (47.1) –
ACR50 response, n/N (%) 24 48/139 (34.5)* 26/138 (18.8)‡ 12/137 (8.8)
52 46/139 (33.1) 38/138 (27.5) –
DAS28-CRP, mean change from baseline ± SE 24 −1.56 ± 0.09* −1.24 ± 0.1‡ −0.64 ± 0.13
52 −1.61 ± 0.09 −1.41 ± 0.10 –
PASI 75 response, n/N (%)b 24 29/62 (46.8)* 34/68 (50.0)‡ 6/59 (10.2)
52 46/62 (74.2) 41/68 (60.3) –
SF-36 PCS, mean change from baseline ± SE 24 6.46 ± 0.59§ 3.42 ± 0.60 2.94 ± 0.83
52 6.43 ± 0.66 4.49 ± 0.68 –
PASI 90 response, n/N (%)b 24 21/62 (33.9)§ 25/68 (36.8) 4/59 (6.8)
52 34/62 (54.8) 28/68 (41.2) –
HAQ-DI score, mean change from baseline ± SE 24 − 0.38 ± 0.04§ − 0.27 ± 0.04 −0.17 ± 0.06
52 −0.43 ± 0.05 −0.30 ± 0.05 –
Patients with resolution of dactylitis, n/N (%)c 24 22/46 (47.8)§ 14/36 (38.9) 5/36 (13.9)
52 28/46 (60.9) 19/36 (52.8) –
Patients with resolution of enthesitis, n/N (%)c 24 35/88 (39.8)§ 35/95 (36.8) 15/98 (15.3)
52 47/88 (53.4) 44/95 (46.3) –
Patient’s assessment of PsA pain (VAS), mean change
from baseline ± SE
24 −18.23 ± 1.97* −12.46 ± 2.0‡ −3.75 ± 2.81
52 −20.3 ± 2.1 −11.8 ± 2.2 –
FACIT-Fatigue, mean change from baseline ± SE 24 6.40 ± 0.78† 2.73 ± 0.80 2.07 ± 1.05
52 6.72 ± 0.9 3.25 ± 0.9 –
Data presented as nonresponder imputation and rescue penalty (binary variables) and mixed-model repeated measures and rescue penalty (continuous variables)
ACR20/50 20%/50% improvement in American College of Rheumatology response criteria; BSA body surface area, DAS28-CRP 28-joint Disease Activity Score using
C-reactive protein, FACIT-Fatigue Functional Assessment of Chronic Illness Therapy—Fatigue, HAQ-DI Health Assessment Questionnaire—Disability Index, N number
of patients, PASI Psoriasis Area Severity Index, PsA psoriatic arthritis, SE standard error, SF-36 PCS Short Form-36 Physical Component Summary, VAS visual
analog scale
*p < 0.0001, †p < 0.001, §p < 0.01, ‡p < 0.05 versus placebo. p values adjusted for multiplicity of testing for overall population data (except for pain
and FACIT-Fatigue)
aPrespecified primary and secondary endpoints were analyzed according to a statistical hierarchy except for pain and FACIT-Fatigue. Endpoints are shown in the
order of testing
bPASI 75 and PASI 90 denote improvements of 75% and 90%, respectively, in the score on the Psoriasis Area Severity Index. Assessed in patients with psoriasis on
at least 3% of their BSA
cResolution of dactylitis and enthesitis among those patients with these symptoms at baseline: dactylitis, N = 46 (300 mg), 36 (150 mg), and 36 (placebo);
enthesitis, N = 88 (300 mg), 95 (150 mg),and 98 (placebo)
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Discussion
In this phase III trial, self-administration of secukinumab
using an autoinjector in patients with PsA improved the
signs and symptoms, skin measures, and physical func-
tion through 52 weeks of treatment. The ACR20/50
response rates with both secukinumab doses (300 and
150 mg) at week 24 were significantly higher than with
placebo and were sustained through week 52. At week
24, significant outcomes with secukinumab 300 and 150
mg versus placebo were also observed in other clinically
relevant domains of PsA, which were sustained through
week 52. Patients were imputed as nonresponders based
on joint count for all of the binary variables. These non-
responders included patients who were responding to
variables with no/low correlation to joint assessment
(e.g., PASI 75/90) at week 16. To overcome this, PASI
75/90 responses were also analyzed using a modified,
variable-specific rescue penalty. The modified rescue
penalty showed notably higher response rates for PASI
75 and PASI 90 compared to the original method in
both secukinumab groups, with a minimal increase in
the placebo group.
Results of this study are in agreement with the find-
ings of earlier studies, which also showed significant
improvements in the signs and symptoms of PsA with
secukinumab 300 and 150 mg [6, 16, 18, 21]. Responses
with secukinumab 150 mg observed in the present study,
however, were lower than the responses observed in pre-
vious studies, with no obvious explanation other than
interstudy variation.
In the subgroup analysis by previous anti-TNF use,
clinical responses were observed with secukinumab in
both anti-TNF-naïve and anti-TNF-IR populations, with
responses generally greater in the anti-TNF-naïve sub-
group. Substantial evidence suggests that treatment with
anti-TNF agents reduces disease activity in patients with
Table 3 Safety profile during the placebo-controlled period and the entire safety-reporting period
Variable Through week 16 (placebo-controlled period) Entire safety-data period
Secukinumab
300 mg (N = 139)
Secukinumab




300 mg (N = 204)
Any secukinumab
150 mg (N = 202)
Any secukinumab
(N = 406)
Exposure to study treatment (days),
mean ± SD
403.8 ± 108.3 392.3 ± 115.8 398.1 ± 112.1
Any AE 76 (54.7) 80 (58.0) 77 (56.2) 164 (194.9) 156 (192.5) 320 (193.7)
Any serious AE 3 (2.2) 5 (3.6) 9 (6.6) 19 (8.8) 21 (10.2) 40 (9.5)
Discontinued due to AEsa 3 (2.2) 5 (3.6) 5 (3.6) 9 (4.4) 13 (6.4) 22 (5.4)
Deathb 0 0 0 0 2 (1.0) 2 (0.5)
Common AEsc
Nasopharyngitis 13 (9.4) 11 (8.0) 13 (9.5) 47 (25.0) 30 (15.5) 77 (20.2)
Upper respiratory tract infection 7 (5.0) 6 (4.3) 5 (3.6) 23 (10.9) 19 (9.3) 42 (10.1)
Diarrhea 4 (2.9) 7 (5.1) 2 (1.5) 16 (7.5) 15 (7.2) 31 (7.4)
Back pain 5 (3.6) 4 (2.9) 1 (0.7) 16 (7.5) 12 (5.7) 28 (6.6)
Headache 6 (4.3) 9 (6.5) 6 (4.4) 11 (5.1) 15 (7.3) 26 (6.1)
Arthralgia 4 (2.9) 1 (0.7) 1 (0.7) 12 (5.5) 13 (6.3) 25 (5.9)
Bronchitis 3 (2.2) 2 (1.4) 5 (3.6) 15 (6.9) 9 (4.3) 24 (5.6)
Fatigue 5 (3.6) 4 (2.9) 2 (1.5) 7 (3.2) 15 (7.3) 22 (5.2)
Urinary tract infection 6 (4.3) 3 (2.2) 2 (1.5) 13 (6.0) 9 (4.2) 22 (5.1)
AEs of special interest
Myocardial infarction 0 0 0 0 1 (0.5) 1 (0.2)
Neutropenia 0 0 0 1 (0.4) 2 (0.9) 3 (0.7)
Candida infection 0 2 (1.4) 2 (1.5) 6 (2.7) 8 (3.8) 14 (3.2)
IBD 0 0 1 (0.7) 1 (0.4) 0 1 (0.2)
Data are number (%) or number (incidence per 100 patient-years). In the analysis of the entire study period, the secukinumab groups include any patients who re-
ceived the stated dose of secukinumab, including those who were randomly assigned to the placebo group at baseline and who underwent a second
randomization to active treatment at week 16/24
AE adverse event, IBD inflammatory bowel disease, N number of patients, SD standard deviation
aExposure-adjusted incidence rates were not calculated for discontinuations because of AEs and death
bTwo deaths reported in the secukinumab 150 mg group: one due to pancreatic carcinoma and one due to small cell lung cancer on day 173 and day
227, respectively
cThe most common AEs are reported as the preferred terms from the Medical Dictionary for Regulatory Activities and occurred at an incidence of at least 5 per 100
patient-years in the pooled secukinumab group during the entire treatment period
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PsA [5–7]. However, some patients do not tolerate or
respond well to these agents, and these refractory pa-
tients are commonly managed by switching from one
anti-TNF to another. Glintborg et al. [22] reported that
switching of anti-TNF agents in PsA patients was associ-
ated with decreasing ACR20 response rates from 47%
with first-line anti-TNF therapy to 22% and 18% among
patients switching to a second or third biologic, respect-
ively. In this study, more than 50% of the patients in the
anti-TNF-IR subgroup had received two or three anti-
TNF agents and the ACR20 response rates at week 24
were 40.9% (secukinumab 300 mg) and 34.1% (secukinu-
mab 150 mg). Higher responses observed with secukinu-
mab 300 mg compared with 150 mg in patients
previously exposed to anti-TNF agents are consistent
with previous studies [6, 15, 16, 18] and provide add-
itional supporting evidence that secukinumab 300 mg is
an appropriate treatment option for this group of pa-
tients. Improvements with secukinumab through 52
weeks were similar in both concomitant MTX and with-
out MTX subgroups.
This study showed the utility of the autoinjector
device. More than 88% of patients were satisfied using
the autoinjector and reported little or no pain at all.
Moreover, the majority of the patients found usage of an
autoinjector easy or very easy, with no external help re-
quired. These observations are in agreement with those
recently reported for the secukinumab autoinjector in
the psoriasis JUNCTURE trial [23].
The safety profile of secukinumab in this study was
based on 398.1 patient-years of exposure to any secukinu-
mab dose and showed no new or unexpected safety sig-
nals, and was consistent with earlier reports of
secukinumab in PsA [16] and psoriasis [13]. The overall
incidence of AEs up to week 16 was comparable between
secukinumab dose groups and placebo. No dose depend-
ence was observed for secukinumab. The majority of the
AEs reported during the entire treatment period were
nonserious and mild to moderate. All serious AEs in any
secukinumab group for the entire treatment period were
single events with no specific trends or clusters. The rate
of discontinuations because of AEs with secukinumab was
low, with two deaths reported during the study. Candida
infections were reported more frequently with secukinu-
mab (3.4%) than with placebo (1.5%); all were manageable
with no treatment discontinuations. Since IL-17 plays a
role in mucocutaneous defense against bacterial and fun-
gal infections [24], continuous observation for candida in-
fections is needed for these patients. Immunogenicity with
secukinumab was low and was not associated with a loss
of efficacy or with immunogenicity-related AEs.
This study has some limitations. This trial was not
designed to identify a difference between doses. The
long-term efficacy and safety of secukinumab compared
to placebo could not be determined as patients on pla-
cebo had to be given rescue medication after a short
period due to ethical consideration and study design,
which was consistent with clinical trials of other biologic
agents.
Conclusions
In summary, self-administration of subcutaneous secuki-
numab provided sustained improvements at 52 weeks
across multiple clinical domains in patients with active
PsA. Patients reported high levels of satisfaction with the
autoinjector and considered it easy to use and not pain-
ful. The safety profile of secukinumab showed no new or
unexpected safety signals during this time.
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